89Zr-PET imaging in humans: a systematic review

Feo, Maria Silvia De; Pontico, Mariano; Frantellizzi, Viviana; Corica, Ferdinando; Cristofaro, Flaminia De; Vincentis, Giuseppe De

doi:10.1007/s40336-021-00462-9

Cited by 25 publications

(13 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A systematic review by De Feo et al supported the use of Zirconium-labelled compounds for PET imaging [28]. It can help to identify patients who may benefit from a specific therapy through the application of radiolabelled antibodies as well as to monitor therapy outcomes.…”

Section: Zirconium-labelled Radiopharmaceuticalsmentioning

confidence: 99%

PET in bladder cancer imaging

Muin¹,

Laukhtina

Hacker³

et al. 2023

Current Opinion in Urology

View full text Add to dashboard Cite

Purpose of reviewThe aim of this study was to summarize the available evidence on different PET imaging modalities for the staging of patients diagnosed with bladder cancer (BCa). We further discuss the use of PET/computed tomography (CT) and PET/MRI with different radiopharmaceuticals to characterize tumour biology for treatment guidance. Recent findingsAvailable evidence supports the benefits of PET/CT in BCa staging due to its higher accuracy in the detection of nodal metastases compared with CT alone. The use of PET/MRI is of major future interest due to the higher soft tissue contrast of MRI, which might enable the early detection of the tumour in the bladder. For the time being, the sensitivity of PET/MRI is still too low, when it comes to the diagnosis of early-stage BCa. This is mainly due to the renal excretion of the commonly used [ 18 F]FDG PET tracer, wherefore small lesions in the wall of the bladder can be missed. Novel studies using PET radiopharmaceuticals to target immune checkpoints or other immune cell targets (immunoPET) demonstrated high uptake in tumour lesions with high PD-L1 expression. The use of immunoPET could therefore help identify BCa patients who exhibit PD-L1 positive tumours for systemic immune-therapy. SummaryPET/CT and PET/MRI seem to be promising imaging tools in BCa staging, especially for the detection of lymph node and distant metastases, as they are more accurate than conventional CT. Future clinical trials with novel radiopharmaceuticals and machine-learning driven PET-technologies bear the potential to help in the early detection, staging, monitoring and precision-medicine approach. Specifically, immunoPET is of high future interest, as it could help develop the concept of precision-medicine in the age of immunotherapy.

show abstract

Section: Zirconium-labelled Radiopharmaceuticalsmentioning

confidence: 99%

PET in bladder cancer imaging

Muin¹,

Laukhtina

Hacker³

et al. 2023

Current Opinion in Urology

View full text Add to dashboard Cite

show abstract

“…It was explained that DFO occupies only six coordination sites while Zr(IV) forms octacoordinated complexes. For this reason, alternative bifunctional chelating agents are being evaluated, mostly containing hydroxamate coordinating units [ 85 , 86 , 87 ].…”

Section: Porphyrins As Ligands For Radiometalsmentioning

confidence: 99%

Porphyrins as Chelating Agents for Molecular Imaging in Nuclear Medicine

2022

View full text Add to dashboard Cite

Porphyrin ligands, showing a significant affinity for cancer cells, also have the ability to chelate metallic radioisotopes to form potential diagnostic radiopharmaceuticals. They can be applied in single-photon emission computed tomography (SPECT) and positron emission tomography (PET) to evaluate metabolic changes in the human body for tumor diagnostics. The aim of this paper is to present a short overview of the main metallic radionuclides complexed by porphyrin ligands and used in these techniques. These chelation reactions are discussed in terms of the complexation conditions and kinetics and the complex stability.

show abstract

“…Numerous advantages of zirconium-89 ( 89 Zr), such as the long half-life of 78.4 h matching the pharmacokinetic behaviour of antibodies, its relatively low average positron energy of 395 keV resulting in low positron range (3.6 mm in water) for high-resolution PET imaging, and good in vivo stability, make it a suitable candidate for labelling of mAb [7][8][9]. For 89 Zr immunoPET imaging, the higher sensitivity of SiPM-based PET/CT systems could be particularly beneficial as the low positron abundance (22.7%) causes the acquired PET images to have a low signal-to-noise level.…”

Section: Introductionmentioning

confidence: 99%

Optimisation of scan duration and image quality in oncological 89Zr immunoPET imaging using the Biograph Vision PET/CT

Sluis

Boellaard

Dierckx

et al. 2023

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Purpose Monoclonal antibody (mAb)-based PET (immunoPET) imaging can characterise tumour lesions non-invasively. It may be a valuable tool to determine which patients may benefit from treatment with a specific monoclonal antibody (mAb) and evaluate treatment response. For 89Zr immunoPET imaging, higher sensitivity of state-of-the art PET/CT systems equipped with silicon photomultiplier (SiPM)-based detector elements may be beneficial as the low positron abundance of 89Zr causes a low signal-to-noise level. Moreover, the long physical half-life limits the amount of activity that can be administered to the patients leading to poor image quality even when using long scan durations. Here, we investigated the difference in semiquantitative performance between the PMT-based Biograph mCT, our clinical reference system, and the SiPM-based Biograph Vision PET/CT in 89Zr immunoPET imaging. Furthermore, the effects of scan duration reduction using the Vision on semiquantitative imaging parameters and its influence on image quality assessment were evaluated. Methods Data were acquired on day 4 post 37 MBq 89Zr-labelled mAb injection. Five patients underwent a double scan protocol on both systems. Ten patients were scanned only on the Vision. For PET image reconstruction, three protocols were used, i.e. one camera-dependent protocol and European Association of Nuclear Medicine Research Limited (EARL) standards 1 and 2 compliant protocols. Vision data were acquired in listmode and were reprocessed to obtain images at shorter scan durations. Semiquantitative PET image parameters were derived from tumour lesions and healthy tissues to assess differences between systems and scan durations. Differently reconstructed images obtained using the Vision were visually scored regarding image quality by two nuclear medicine physicians. Results When images were reconstructed using 100% acquisition time on both systems following EARL standard 1 compliant reconstruction protocols, results regarding semiquantification were comparable. For Vision data, reconstructed images that conform to EARL1 standards still resulted in comparable semiquantification at shorter scan durations (75% and 50%) regarding 100% acquisition time. Conclusion Scan duration of 89Zr immunoPET imaging using the Vision can be decreased up to 50% compared with using the mCT while maintaining image quality using the EARL1 compliant reconstruction protocol.

show abstract

89Zr-PET imaging in humans: a systematic review

Cited by 25 publications

References 72 publications

PET in bladder cancer imaging

PET in bladder cancer imaging

Porphyrins as Chelating Agents for Molecular Imaging in Nuclear Medicine

Optimisation of scan duration and image quality in oncological 89Zr immunoPET imaging using the Biograph Vision PET/CT

Contact Info

Product

Resources

About